Yahoo Finance • 15 days ago
* Allarity Therapeutics (NASDAQ:ALLR [https://seekingalpha.com/symbol/ALLR]) prospectus covers up to 1.56M shares of common stock offered by a selling stockholder. * Shares consist of: 760,916 common shares, and 801,584 shares issuabl... Full story
Yahoo Finance • 18 days ago
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients continue on therapy now... Full story
Yahoo Finance • 23 days ago
TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pat... Full story
Yahoo Finance • last month
Unusual volume stocks are being observed in Wednesday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT INHD [https://www.chartmill.com/stock/quote/INHD/profile] 31.57% INNO HOLDINGS INC (NASDAQ:I... Full story
Yahoo Finance • last month
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 90.28% INVIVYD INC'S... Full story
Yahoo Finance • last month
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today. [mostactive] TOP MOST ACTIVE STOCKS TICKER CHANGE COMMENT IXHL [https://www.chartmill.com/stock/quote... Full story
Yahoo Finance • last month
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT NUKKW [https://www.ch... Full story
Yahoo Finance • last month
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Allarity Therapeutics Inc. 196,807,150 2.28 1.75 1.84 +0.8987 Incannex H... Full story
Yahoo Finance • last month
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT HKPD [https://www.chartmill.com/s... Full story
Yahoo Finance • last month
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 132.0% Investors witness... Full story
Yahoo Finance • last month
TARPON SPRINGS, Fla. - Allarity Therapeutics, Inc. (NASDAQ:ALLR), a small-cap biotech company with a market capitalization of $14.45 million, announced Tuesday that the U.S. Food and Drug Administration has granted Fast Track designation t... Full story
Yahoo Finance • last month
Allarity Therapeutics, Inc. TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differenti... Full story
Yahoo Finance • 2 months ago
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic - Secured new service contract with EU b... Full story
Yahoo Finance • 3 months ago
TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story
Yahoo Finance • 3 months ago
* Allarity Therapeutics (NASDAQ:ALLR [https://seekingalpha.com/symbol/ALLR]) announced on Monday the appointment of Jeff Ervin as the company’s new chief financial officer (CFO). * Ervin succeeds Alexander Epshinsky, who will remain e... Full story
Yahoo Finance • 3 months ago
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story
Yahoo Finance • 3 months ago
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story
Yahoo Finance • 3 months ago
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story
Yahoo Finance • 4 months ago
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story
Yahoo Finance • 4 months ago
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story